Last reviewed · How we verify

NCT06885346

Probiotics Improve Adult Allergic Rhinitis and Regulate Gut Microbiota

Completed NA Last updated 20 March 2025
What this trial tests

NA trial testing Probiotic in Allergic Rhinitis in 78 participants. Completed in 25 February 2025.

Timeline
2 November 2024
Primary endpoint
28 December 2024
25 February 2025

Quick facts

Lead sponsorWecare Probiotics Co., Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment78
Start date2 November 2024
Primary completion28 December 2024
Estimated completion25 February 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Wecare Probiotics Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Probiotic

Trials testing the same drug.

Other recruiting trials for Allergic Rhinitis

Currently open trials in the same condition.

Other Wecare Probiotics Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06885346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing